Daito Pharmaceutical Co.,Ltd. (TYO:4577)
Japan · Delayed Price · Currency is JPY 1,329.00
+35.00 (2.70%)
Jul 14, 2026, 3:30 PM JST
Daito Pharmaceutical Income Statement
Financials in millions JPY. Fiscal year is June - May.
Millions JPY. Fiscal year is Jun - May.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | May '26 May 31, 2026 | May '25 May 31, 2025 | May '24 May 31, 2024 | May '23 May 31, 2023 | May '22 May 31, 2022 |
| 50,650 | 50,643 | 46,895 | 45,101 | 43,464 | |
Revenue Growth (YoY) | 0.01% | 7.99% | 3.98% | 3.77% | -10.78% |
Cost of Revenue | 40,753 | 42,005 | 37,056 | 34,770 | 32,005 |
Gross Profit | 9,897 | 8,638 | 9,839 | 10,331 | 11,459 |
Selling, General & Admin | 6,260 | 3,333 | 3,431 | 3,082 | 3,004 |
Research & Development | - | 2,520 | 2,349 | 1,865 | 1,749 |
Operating Expenses | 6,260 | 6,017 | 5,945 | 5,119 | 4,891 |
Operating Income | 3,637 | 2,621 | 3,894 | 5,212 | 6,568 |
Interest Expense | -130 | -123 | -41 | -12 | -9 |
Interest & Investment Income | 68 | 64 | 65 | 57 | 55 |
Earnings From Equity Investments | 87 | 75 | - | - | - |
Currency Exchange Gain (Loss) | 102 | 34 | -23 | -91 | 22 |
Other Non Operating Income (Expenses) | 47 | 33 | 29 | 4 | 93 |
EBT Excluding Unusual Items | 3,811 | 2,704 | 3,924 | 5,170 | 6,729 |
Gain (Loss) on Sale of Investments | 331 | 409 | 326 | -87 | 47 |
Asset Writedown | -315 | -384 | -165 | -17 | -56 |
Other Unusual Items | 237 | 228 | 134 | 11 | - |
Pretax Income | 4,064 | 2,957 | 4,219 | 5,077 | 6,720 |
Income Tax Expense | 928 | 1,192 | 1,040 | 1,549 | 2,092 |
Earnings From Continuing Operations | 3,136 | 1,765 | 3,179 | 3,528 | 4,628 |
Minority Interest in Earnings | 25 | 143 | 116 | 72 | 40 |
Net Income | 3,161 | 1,908 | 3,295 | 3,600 | 4,668 |
Net Income to Common | 3,161 | 1,908 | 3,295 | 3,600 | 4,668 |
Net Income Growth | 65.67% | -42.09% | -8.47% | -22.88% | 9.94% |
Shares Outstanding (Basic) | 29 | 30 | 31 | 32 | 31 |
Shares Outstanding (Diluted) | 29 | 30 | 31 | 32 | 31 |
Shares Change (YoY) | -3.31% | -3.06% | -0.86% | 3.38% | 1.94% |
EPS (Basic) | 107.46 | 62.72 | 105.00 | 113.82 | 152.45 |
EPS (Diluted) | 107.46 | 62.72 | 105.00 | 113.71 | 152.45 |
EPS Growth | 71.34% | -40.27% | -7.67% | -25.41% | 7.85% |
Free Cash Flow | 5,559 | -892 | -1,038 | -1,350 | -257 |
Free Cash Flow Per Share | 188.99 | -29.32 | -33.08 | -42.65 | -8.39 |
Dividend Per Share | - | 35.000 | 30.000 | 27.273 | 22.727 |
Dividend Growth | - | 16.67% | 10.00% | 20.00% | 8.70% |
Gross Margin | 19.54% | 17.06% | 20.98% | 22.91% | 26.36% |
Operating Margin | 7.18% | 5.17% | 8.30% | 11.56% | 15.11% |
Profit Margin | 6.24% | 3.77% | 7.03% | 7.98% | 10.74% |
Free Cash Flow Margin | 10.97% | -1.76% | -2.21% | -2.99% | -0.59% |
EBITDA | 8,024 | 6,953 | 7,553 | 9,082 | 9,881 |
EBITDA Margin | 15.84% | 13.73% | 16.11% | 20.14% | 22.73% |
D&A For EBITDA | 4,387 | 4,332 | 3,659 | 3,870 | 3,313 |
EBIT | 3,637 | 2,621 | 3,894 | 5,212 | 6,568 |
EBIT Margin | 7.18% | 5.17% | 8.30% | 11.56% | 15.11% |
Effective Tax Rate | 22.84% | 40.31% | 24.65% | 30.51% | 31.13% |